Arrowstreet Capital, Limited Partnership Mirati Therapeutics, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $244,123 - $553,018	6,234 New	6,234 $418,000
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $7.62 Million - $9.51 Million	-52,900 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $11.2 Million - $15.7 Million	-70,650 Reduced 57.18%	52,900 $9.06 Million
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $20 Million - $29.7 Million	123,550 New	123,550 $27.1 Million
Q4 2019 Feb 13, 2020	SELL	$70.76 - $128.86 $970,473 - $1.77 Million	-13,715 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $1.07 Million - $1.5 Million	13,715 New	13,715 $1.07 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.